Analyst Ratings For NASDAQ:BOLD – Audentes Therapeutics (NASDAQ:BOLD)
Today, HC Wainwright raised its price target on NASDAQ:BOLD – Audentes Therapeutics (NASDAQ:BOLD) to per share.
Some recent analyst ratings include
- 5/17/2018-William Blair Reiterated Rating of Buy.
- 5/11/2018-Raymond James Reiterated Rating of Hold.
- 3/9/2018-Cowen Reiterated Rating of Buy.
- 2/12/2018-Mizuho initiated coverage with a Neutral ➝ Neutral rating.
Recent Insider Trading Activity For NASDAQ:BOLD – Audentes Therapeutics (NASDAQ:BOLD)
NASDAQ:BOLD – Audentes Therapeutics (NASDAQ:BOLD) has insider ownership of 47.30% and institutional ownership of 69.43%.
- On 4/2/2018 Matthew R Patterson, CEO, sold 700 with an average share price of $30.01 per share and the total transaction amounting to $21,007.00.
- On 3/29/2018 Suyash Prasad, VP, sold 7,800 with an average share price of $30.03 per share and the total transaction amounting to $234,234.00.
- On 3/26/2018 Louis G Lange, Director, sold 48,000 with an average share price of $28.89 per share and the total transaction amounting to $1,386,720.00.
- On 3/26/2018 Suyash Prasad, VP, sold 1,900 with an average share price of $30.00 per share and the total transaction amounting to $57,000.00.
- On 3/15/2018 Mary Newman, SVP, sold 10,000 with an average share price of $30.36 per share and the total transaction amounting to $303,600.00.
- On 3/12/2018 Orbimed Advisors Llc, Major Shareholder, sold 156,431 with an average share price of $34.97 per share and the total transaction amounting to $5,470,392.07.
- On 3/8/2018 Orbimed Advisors Llc, Major Shareholder, sold 58,428 with an average share price of $34.06 per share and the total transaction amounting to $1,990,057.68.
Recent Trading Activity for NASDAQ:BOLD – Audentes Therapeutics (NASDAQ:BOLD)
Shares of NASDAQ:BOLD – Audentes Therapeutics closed the previous trading session at 35.97 up +2.02 5.95% with 34.22999954223633 shares trading hands.